Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case

Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case

Lung cancer holds a leading position in the cancer mortality pattern worldwide. The emergence of knowledge about driver mutations heralded a new era in the targeted therapy for lung carcinomas. ALK translocation is identified in 5–7% of non-small cell lung cancer cases. ALK-positive lung adenocarcin...

Full description

Bibliographic Details
Main Authors: A. V. Sultanbaev, Sh. I. Musin, K. V. Menshikov, A. F. Nasretdinov, B. A. Ibragimov, A. G. Nigmatullin, R. T. Ayupov, A. A. Izmailov, N. I. Sultanbaeva
Format: Article
Language:Russian
Published: Remedium Group LLC 2020-12-01
Series:Медицинский совет
Subjects:
non-small cell lung cancer
adenocarcinoma
alk translocation
alk inhibitors
alectinib
progression-free survival
Online Access:https://www.med-sovet.pro/jour/article/view/5954

Internet

https://www.med-sovet.pro/jour/article/view/5954

Similar Items